OBI PHARMA
OBI PHARMA
Social Links:
Industry:
Biotechnology Pharmaceutical
Address:
Taipei, T'ai-pei, Taiwan
Country:
Taiwan
Website Url:
http://www.obipharma.com
Status:
Active
Similar Organizations
Dongkoo Bio&Pharma
Dongkoo Bio&Pharma is an bio&Pharma Company.
Official Site Inspections
http://www.obipharma.com Semrush global rank: 1.24 M Semrush visits lastest month: 24.25 K
- Host name: 76.76.21.21
- IP address: 76.76.21.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "OBI Pharma"
HOME - OBI Pharma 台灣浩鼎
OBI-992 Shortlisted as the Most Promising Clinical Candidate in the 11th Annual World ADC Awards. OBI Pharma, Inc. (4174.TWO), a clinical-stage oncology company, announced that OBI-992, a TROP2 targeted antibody-drug …See details»
People and Culture - OBI Pharma 台灣浩鼎
OBI focuses on innovative research and development for cancer therapies and aims to develop “first-in-class” and “best-in-class” ground-breaking drugs. It aspires to market these drugs …See details»
OBI Pharma, Inc. - Wikipedia
The company was founded by Micheal N.Chang on April 29, 2002. It was formerly a subsidiary of Optimer Pharmaceuticals. On 9 Feb 2007, its parent company Optimer Pharmaceuticals can buy/sell on Nasdaq Stock Exchange. At that time, its share price was US$8.50 per share. On 15 May 2012, OBI Pharma, Inc. was approved to become a public company in Taiwan. See details»
OBI Pharma - LinkedIn
OBI Pharma Inc. (OBI) is a global clinical stage oncology company that is headquartered in Taiwan. The company also has subsidiaries in the United States and Australia. It was founded in 2002 by ...See details»
Company OBI Pharma, Inc. - MarketScreener.com
Feb 6, 2013 OBI Pharma, Inc. is a Taiwan-based company principally engaged in the development of new pharmaceuticals. The Company mainly operates its businesses through …See details»
OBI Pharma Announces Executive Leadership Management …
Jun 2, 2023 I am impressed with the dedication and accomplishments of the organization to date. Additionally, with OBI’s innovative cancer pipeline under clinical trials to address unmet …See details»
OBI Pharma, Inc | LinkedIn
OBI Pharma, Inc | 2,134 followers on LinkedIn. Developing novel therapeutic agents for patients with unmet medical needs. | OBI Pharma Inc. (OBI) is a global clinical stage oncology …See details»
Corporate Overview - OBI Pharma 台灣浩鼎
Apr 29, 2002 OBI Pharma, Inc. Stock Code 4174.TWO Market Taipei Exchange Industry Type Biotech & Medical Care Principal Activities New drugs research Date of Establishment …See details»
OBI Pharma CEO and Key Executive Team | Craft.co
OBI Pharma's Director is Tamon Tseng. Other executives include Yun Yen, Director; Ming-Tain Lai, Chief Scientific Officer and 3 others. See the full leadership team at Craft.See details»
OBI PHARMA, INC. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for OBI PHARMA, INC. of Taipei City, Taipei. Get the latest business insights from Dun & Bradstreet.See details»
OBI Pharma Announces Executive Leadership Management …
Jun 2, 2023 Additionally, with OBI’s innovative cancer pipeline under clinical trials to address unmet medical needs, it is an exciting time to join the organization,” stated Dr. Wang. Dr. …See details»
OBI Pharma - Craft
Sep 25, 2024 OBI Pharma has 1 employees across 3 locations and NT$41.55 m in annual revenue in FY 2023. See insights on OBI Pharma including office locations, competitors, …See details»
Who We Are - OBI Pharma 台灣浩鼎
Adagloxad Simolenin (OBI-822) was approved to carry out phase III human clinical trial in Poland and Brazil. OBI-833 was reviewed by Taiwan Food and Drug Administration (TFDA) of the …See details»
Biosion's Partner OBI Pharma Announces FDA Clearance of IND …
Jan 8, 2024 The Partner of Biosion Inc. (Biosion) , OBI Pharma (4174.TWO), announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) …See details»
OBI Pharma Granted U.S. FDA Orphan Drug Designation for the …
TAIPEI, Taiwan, Jan. 21, 2020 /PRNewswire/ -- OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), today announced that the U.S. Food and Drug Administration (FDA) has …See details»
Investor Overview - OBI Pharma 台灣浩鼎
OBI-992 Ranks Among World ADC Award Top 8, Stands Strong Among Global Pharma Giants Despite Missing Top Prize, Gains Global RecognitionSee details»
OBI Pharma Announces Phase 2 Studies Patient Enrollment for OBI …
TAIPEI, Taiwan, Jan. 24, 2022 /PRNewswire/ -- OBI Pharma, a Taiwan biopharma company (TPEx: 4174), today announced that the first patients have been enrolled in both of the Phase …See details»
Innovative Products + Flexible Business Models - obipharma.com
OBI Pharma (4174.TWO) held an investor conference this afternoon (12/2), where CEO, Dr. Heidi Wang, unveiled the company’s five-year vision. Leveraging innovative ADC enabling …See details»